Edgewise Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for muscle diseases. The company leverages its proprietary platform to discover and develop treatments that target the underlying mechanisms of muscle disorders, with a particular emphasis on Duchenne muscular dystrophy (DMD) and other rare muscle diseases. Edgewise aims to improve the quality of life for patients by addressing unmet medical needs through its advanced drug development programs.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

9 Patents

#130 in Boulder, CO

#696 in Colorado

#32,588 in US

Boulder, CO, United States of America

Edgewise Therapeutics, Inc.

Forward Citations = 18

20 inventors:

Kevin Koch (9 out of 44 patents)

Alan Russell (9 out of 12 patents)

Stephen T Schlachter (9 out of 51 patents)

4. Kevin W Hunt (9 out of 25 patents)

5. Paul Winship (5 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Edgewise Therapeutics, Inc.. Retrieved from https://idiyas.com/company/edgewise-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

7 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]